Several brokerages have updated their recommendations and price targets on shares of I-Mab (NASDAQ: NBP) in the last few weeks:
- 9/7/2026 – I-Mab was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 8/30/2026 – I-Mab was downgraded by Wall Street Zen from “hold” to “sell”.
- 8/27/2026 – I-Mab had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 8/22/2026 – I-Mab was upgraded by Wall Street Zen from “sell” to “hold”.
- 8/20/2026 – I-Mab had its “buy” rating reaffirmed by HC Wainwright. They now have a $9.00 price target on the stock.
I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.
Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.
Featured Stories
- Five stocks we like better than I-Mab
- Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came First
- Feed to Feat: Can Meta Unlock the AI Agent Cash Machine?
- Chime Finds Its Stride With a $590M Deal That Could Reshape Its Banking Model
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.
